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behaviors by the Porsolt forced swim test, and locomotor 
activity and anxiety by the open field test. We also studied 
adult neurogenesis within the hippocampal dentate gyrus by 
using the thymidine analogue BrdU to label replicating stem 
cells. Ten months after irradiation animals were killed and 
brain tissue used for histology and immunohistochemistry.  
Results: Microbeam irradiation did not alter cognitive 
performance. Interestingly, microbeam irradiation (300 Gy) 
significantly reduced the immobility time in the forced swim 
test without affecting locomotor activity as compared to 
control rats and 5-10 Gy irradiated rats. Histological analysis 
showed that microbeam irradiation did not alter the 
cytoarchitecture of the hippocampus with cell death 
observed only along the irradiation pathway. We did not 
observe a reduction of hippocampal neurogenesis, assessed 
by stereological counts of BrdU-positive cells in the dentate 
gyrus of the hippocampus at 10 months after microbeam 
irradiation.  
Conclusions: These data shed light on the biological effects 
of microbeam irradiation on the CNS and may open new 
potential therapeutic strategies in cancer treatment and 
other CNS disorders. 
Keywords: Microbeam radiation therapy, Hippocampus, 
Neurogenesis  
 
References: 
[1] Sienkiewicz et al, Int J Radiat Biol, 65:611, 1994 
[2] Anschel et al, Neurosurg Rev, 34:133-142, 2011 
[3] Bräuer-Krisch et al, Mutat Res, 704, 160-166, 2010 
[4] Romanelli et al, PLoS One, 8:e53549, 2013 
 
30 
What are the Dominant Radiobiological Mechanisms at Play 
in Stereotactic Radiotherapy? 
D. J. Brenner and I. Shuryak 
Center for Radiological Research, Columbia University 
Medical Center, New York, NY, USA 
 
Recent clinical results using Stereotactic Radiation Therapy 
(SRT) are very encouraging. Our goal is to investigate 
whether the excellent SRT tumor control data imply that 
there are new tumoricidal mechanisms that determine tumor 
control at high SRT doses – new mechanisms which are not 
present or have little effect at conventional radiotherapeutic 
doses.  
To accomplish this, we investigate whether the standard LQ 
model with heterogeneity can provide as good a description 
of the SRT data as can models with extra terms describing 
unique high-dose tumor control mechanisms. 
We analyzed published TCP data for lung tumors or brain 
metastases from 3000 SRT patients, covering a wide range of 
doses and fraction numbers. We used: (a) a linear-quadratic 
model (including heterogeneity), which assumes the same 
mechanisms at all doses, and (b) alternative models with 
terms describing distinct tumoricidal mechanisms at high 
doses. 
Both for lung and brain data, the LQ model provided a 
significantly better fit over the entire range of treatment 
doses than did any of the models requiring extra terms at 
high doses. Analyzing the data as a function of fractionation 
(1 fraction vs. >1 fraction), there was no significant effect on 
TCP in the lung data, whereas for brain data multi-fraction 
SRT was associated with higher TCP than single-fraction 
treatment. 
This analysis suggests that distinct tumoricidal mechanisms 
do not determine tumor control at high doses/fraction. 
Rather the excellent clinical outcomes seen with SRT are the 
result of the excellent dose distributions which SRT provides, 
which allow delivery of larger doses to the tumor than is 
possible with conventional radiotherapy. Finally, there is 
plausible evidence suggesting that multi-fraction SRT is 
superior to single-dose SRT. 
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Purpose: Image-guided radiotherapy (IGRT) is a technique 
used to optimise RT beam delivery to the tumour by 
following its evolution over time through regular MVCT 
imaging of the treatment area. 
However, its application is limited by clinical concerns over 
the additional dose coming from MVCT imaging, which we 
evaluate in this study. 
Methods: We use the particle transport framework GEANT4[1] 
to model the X-ray beam line from the Tomotherapy Hi-Art 
RT treatment machine at the Addenbrooke's hospital and 
evaluate the imaging dose delivered to the vicinity of the 
tumour. Dose maps are obtained by combining simulations of 
the CT scan using a static beam line with 51 different 
exposition angles. 
All GEANT4 simulations were performed on UK grid 
resources[2] to maximize parallel throughput, using 
anonymised data. 
Results: Simulated beam profiles (PDD, longitudinal and 
lateral) with different MLC beam patterns were compared to 
actual calibration data taken in water tank at Addenbrooke's 
hospital. The agreement between the model and the 
calibration is quantified by the Gamma index[3]. Less than 2% 
of the simulated points exceed Gamma(1%,1mm) 
We also simulated the imaging dose distribution in a prostate 
patient treated in 34 fractions, each fraction starting with 
one MV CT used for image guidance. We used a fan beam 
width of 4 mm with a pitch of 2 mm. The results are shown in 
Figure 1. 
 
 
Figure 1: Normalised imaging dose distributions in Gy for a 
prostate cancer patient, in a transverse plane in the 
treatment region. 
 
The maximum simulated dose is about 1.5 cGy on a single 
MVCT, in agreement with results found in [4] using 
proprietary software. For comparison, the treatment dose in 
the same area goes up to 2 Gy per fraction. 
Conclusions: We have successfully modeled the Megavoltage 
imaging beam line of the Tomotherapy Hi-Art machine used 
for radiotherapy at the Addenbrooke's hospital using Geant 4 
and used it to derive dose maps in the patient. 
Doses were found to be in agreement with other published 
results and negligible with respect to the treatment dose. 
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Glioblastoma multiforme (GBM) is the most common and 
malignant primary brain tumor. The median survival time is 
14.6 months from time of diagnosis, in spite of aggressive 
surgery, radiation therapy and chemotherapy. Only 3 to 5% of 
patients survive more than three years. Recurrence of GBM is 
nearly universal, confers a dismal prognosis with a 6-months 
progression free survival (6M-PFS) rate of 15% to 21% and a 
median survival of 6.2 months. Advancements in the past 
decades have not significantly increased the overall survival 
of patients with this disease. GBM has been demonstrated 
NK-1 receptor system and Substance P can be used as a 
ligand for targeted therapy. Alpha emitter, like 213Bi offers 
the new potential for selective irradiation of tumors, with 
minimizing damage to adjacent tissue.  
Material and methods: 21 patients with primary recurrent 
glia tumor IV after standard therapy were included in the 
study during two years. Following intracavitary or 
intratumoral insertion of 1-2 catheter systems, patients were 
treated with 1–8 doses of 2 GBq 213Bi-DOTA-Substance P (213Bi-
SP) in intervals of 2 months. 68Ga-DOTA-Substance P (68Ga-SP) 
was co-injected with the therapeutic doses to assess 
biodistribution using PET/CT. Therapeutic response was 
monitored with MRI. Study was approved by the ethical 
committee of the Medical University of Warsaw. 
Results: Treatment with activity up to 13 GBq 213Bi-SP was 
tolerated well with only mild transient adverse reactions: in 
1 patient transient increase of focal neurological symptoms 
and in 3 patients episodes of epileptic seizures several days 
after treatment. PET/CT imaging showed high retention of 
the radiolabeled peptide at the tumor site.  
Out of 21 evaluable patients, 17 progressed within the 
follow-up period, 5 of them are alive at the end of follow-up. 
Four patients were excluded from evaluation due to lack of 
data. Median progression free survival was 3.7 months, with a 
6 months progression free survival rate of 19% . The median 
overall survival from the first diagnosis was 25.2 months, and 
from the start of 213Bi-SP was 6.5 months. Follow up of 
therapeutic responses and toxicity is continued and patient 
recruitment is ongoing. Busk 
 
Conclusions: Treatment of recurrent GBM with 213Bi-SP is safe 
and well tolerated. Targeted alpha therapy with 213Bi-SP may 
evolve as a promising novel option for treatment of recurrent 
GBM. 
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A high-resolution silicon detector probe, in coincidence with 
a conventional  
PET scanner, is expected to provide images of higher spatial 
resolution than those achievable using the scanner alone, due 
to the finer pixelization of the probe detector[1]. A PET-
probe prototype is being developed utilizing this principle 
[2]. The system includes a probe consisting of ten layers of 
silicon detectors, each a 80×52 array of 1×1×1 mm3 pixels, to 
be operated in coincidence with a modern clinical PET 
scanner. Detailed simulation studies of this system have been 
performed to assess the effect of the additional probe 
information on the quality of the reconstructed images.  
Using the Monte-Carlo simulation package GATE, a grid of 
point sources was simulated to study the contribution of the 
probe to the system resolution at different locations over the 
field of view (FOV). A resolution phantom was used to 
demonstrate the effect on image resolution for two probe 
positions. A homogeneous source distribution with hot and 
cold regions was used to demonstrate that the localized 
improvement in resolution does not come at the expense of 
the overall quality of the image. An imaging study using 
experimental probe data was also performed. The list-mode 
maximum likelihood–expectation maximization (ML–EM) 
algorithm[3] was used for image reconstruction in all cases.  
As expected, the point spread function of the PET-probe 
system was found to be non-isotropic and vary with position, 
offering improvement in specific regions. An increase in 
resolution, of factors of up to 2, was observed in the region 
close to the probe. Images of the resolution phantom showed 
visible enhancement in resolution when including the probe 
in the simulations, as can be seen in figure 1. The image 
quality study demonstrated that contrast and spill-over ratio 
in other areas of the FOV were not sacrificed for this 
enhancement. The improvement in resolution when using the 
Si detector probe was also observed using the experimental 
prototype. In this context, previously unrecoverable features 
in a resolution phantom could be resolved when probe data 
was included during image reconstruction. Remaining 
challenges in developing the PET-probe system include 
overcoming the limitations imposed by the timing 
performance of the Si detectors and more detailed system 
modeling in image reconstruction.    
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Figure 1: Images of the resolution phantom reconstructed 
using data from the probe and from the scanner alone. The 
probe is located to the right of the image, in close proximity 
to the phantom.  The phantom features are 4.8, 4.0, 3.2, 2.4, 
1.6 and 1.2 mm in diameter. Pixels are 1 × 1 × 1 mm3 
